The US approved an Alzheimer’s drug. Seven patients subsequently died.
Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved ...
The European Commission refers lecanemab decision to Appeal Committee
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission (EC) has decided to refer ...
The Pharma Letter1h
EC refers lecanemab decision to Appeal Committee
Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) today provided an update on the ongoing regulatory review of the Marketing ...
STAT22h
Emotional whiplash for PTC Therapeutics
Pluvicto, Novartis’ blockbuster radiopharmaceutical for prostate cancer, has been greenlighted by the FDA for use earlier in ...
WFYI17h
Eli Lilly’s Alzheimer’s drug not recommended by top European regulator
Eli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the ...
Zacks Investment Research on MSN22h
Is the Future Bleak for SAVA Stock Following Another Setback?
Cassava Sciences SAVA recently suffered yet another setback, which raises concern regarding its prospects. Last week, the company announced that the phase III study REFOCUS-ALZ on lead pipeline ...